Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer

doi:10.4251/wjgo.v15.i9.1626

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 9

This Article

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5732)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

165

WORD

HTML

2632

Figures (1-1)

561

Tables (1-3)

512

Sum=3899

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

372

Download

1253

Sum=1625

Sep 15, 2023 (publication date) through Mar 2, 2026

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Sep 15, 2023; 15(9): 1626-1635
Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1626

Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer

Yakup Duzkopru, Abdulkadir Kocanoglu, Ozlem Dogan, Hayriye Sahinli, Ebru Cilbir, Mustafa Altinbas

Yakup Duzkopru, Abdulkadir Kocanoglu, Ozlem Dogan, Hayriye Sahinli, Ebru Cilbir, Mustafa Altinbas, Department of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey

Author contributions: Duzkopru Y and Kocanoglu A performed the study concept, study design, and statistical analysis; Dogan O and Cilbir E contributed to the data acquisition, data analysis and interpretation; Altinbas M and Sahinli H performed the manuscript editing; All authors contributed to the article and approved the submitted version.

Institutional review board statement: The ethics committee approval of the study was given by the Diskapi Yıldırım Beyazıt Training and Research Hospital ethics committee (date: 26.07.2021), No. 116/21.

Informed consent statement: The Institutional Review Board waived the need for informed consent due to the study's retrospective methodology.

Conflict-of-interest statement: The authors declare no conflict of interest.

Data sharing statement: The raw data supporting the conclusions of this article will be made available without restriction by the authors.

Corresponding author: Yakup Duzkopru, MD, Academic Fellow, Doctor, Department of Medical Oncology, Ankara Etlik City Hospital, Varlik Neighbourhood, Halil Sezai Erkut Street, Yenimahalle, Ankara 06170, Turkey. yakupduzkopru@gmail.com

Received: April 26, 2023
Peer-review started: April 26, 2023
First decision: June 7, 2023
Revised: June 17, 2023
Accepted: July 29, 2023
Article in press: July 29, 2023
Published online: September 15, 2023
Processing time: 139 Days and 14 Hours

Abstract

BACKGROUND

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies.

AIM

To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer.

METHODS

The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and platelet/lymphocyte ratio were determined using receiver operating characteristic analysis. Low HALP scores were defined as those less than 24.79 and high HALP scores as those greater than 24.79.

RESULTS

The study cohort comprised 147 patients and 110 of them (74.8%) were male. The patients' median age was 63 (22-89) years. The median overall survival was significantly superior in the patients with high HALP scores than in those with low HALP scores (10.4 mo vs 7.5 mo, respectively; P < 0.001)

CONCLUSION

The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.

Keywords: Biomarker; Hemoglobin, albumin, lymphocyte, and platelet score; Gastric cancer; Nutritional index; Prognosis; Survival

Core Tip: Median overall survival (OS) was 10.4 mo in the high hemoglobin, albumin, lymphocyte, and platelet (HALP) group and 7.5 mo in the low HALP group. There was a statistically significant difference between the groups in terms of age (P < 0.001), second-line chemotherapy (P < 0.001), sex (P = 0.035), and HALP score (P = 0.004). The HALP score has been demonstrated to be useful as a prognostic factor in a variety of cancer types, including genitourinary and gastrointestinal malignancies. Our study is the first to investigate the HALP score in patients with metastatic gastric cancer. We found that patients with high HALP scores had longer OS. Given its simplicity and low cost, we think the HALP score can be utilized to manage patients with gastric cancer.